Plavix

Subscribe to Plavix

A federal judge in New Jersey recently granted summary judgment to Plavix drug makers Bristol Myers-Squibb Company (“BMS”), Sanofi-Aventis U.S., L.L.C., Sanofi-Aventis U.S., Inc., and Sanofi-Synthelabo, Inc. in a lawsuit alleging that plaintiff’s gastrointestinal bleeding was caused by defendants’ prescription drug Plavix.

Plaintiff alleged that she suffered injuries as a result of defendants’ design, development, manufacture, promoting, marketing, distributing, labeling, and sale of Plavix, an anti-clotting medication.

Plavix was initially approved by the FDA for individuals with recent heart attack, stroke (including Transient Ischemic Attack or “TIA”), or peripheral arterial disease. Plavix inhibits blood platelets from forming clots and therefore increases the risk of bleeding. Its labeling has included information about that risk.

Plaintiff’s complaint asserts product liability related causes of action under California state law, for defective design, manufacturing defect, failure to warn, and negligence.…

Continue Reading Plavix Decision Raises Questions About Learned Intermediary Doctrine

New Jersey was once one of the premiere venues for Mass Tort filings (now termed Multicounty Litigations in New Jersey). One of the reasons for this was the obvious fact that many large pharmaceutical companies maintain their principal place of business in New Jersey, making it very difficult for those pharmaceutical companies to remove cases brought against them in New Jersey Superior Court to federal District Court, due to the “forum defendant” rule (28 U.S.C. § 1441(b)(2)). Perhaps a more significant reason was the makeup of the New Jersey Superior Court’s Mass Tort bench at a time when nationally recognized jurists, such as the late Judge Carol E. Higbee, were on the cutting edge of high-stakes pharmaceutical litigation, like the seminal Vioxx cases.
…
Continue Reading SCOTUS Decision in Plavix Litigation Could Lead to a Resurgence in New Jersey Mass Tort Filings

As we have previously reported, Plavix®, manufactured by Sanofi-Aventis and Bristol-Myers Squibb (collectively, “Defendants”), is a blood thinner prescribed to prevent heart attacks, strokes and blood clotting. However, the users of Plavix® have alleged various forms of severe side-effects. Reportedly, these side-effects include: gastrointestinal bleeding, cerebral bleeding, bleeding ulcers, Thrombotic Thrombocytopenic Purpura (TTP), heart…

Plavix®, marketed by Bristol-Myers Squibb and Sanofi Pharmaceuticals, is the second most commonly prescribed drug on the U.S. market to prevent heart attacks and stroke.  The medication, known as a “clopidogrel,” is a blood thinner that belongs to a category of drugs called antiplatelets.  The drug works to prevent blood clots.

 A recent study by…

The United States Department of Justice (“DOJ”) is concerned that the dangers of Plavix® were not properly identified by its manufacturers Sanofi-Aventis and Bristol-Myers Squibb.  The DOJ is concerned that the manufacturers failed to disclose certain information in hopes of misleading consumers about the safety of the drug.  Studies show that certain individuals have a…

Plavix, manufactured by Sanofi-Aventis and Bristol-Myers Squibb (collectively, “Defendants”), is a blood thinner prescribed to prevent heart attacks, strokes and blood clotting. However, the users of Plavix have alleged various forms of severe side-effects. Reportedly, these side-effects include: gastrointestinal bleeding, cerebral bleeding, bleeding ulcers, Thrombotic Thrombocytopenic Purpura (TTP), heart attack, stroke and death.

In February…